Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Agreement between HR and HER2 status from primary and metastatic samples

From: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

  HR status* HER2*  
  ER status K
(ASE) 		PR status K
(ASE) 		HER2 Status K
(ASE)
Total (N) 126   123   121  
Agreement,
N (%) 		      
Yes 98 (78) 0.55 (0.074) 86 (70) 0.31 (0.083) 101 (83) 0.003
(0.019)
No 28 (22)    37 (29)   20 (17)
+ to - 18 (14)    30 (24)   20 (17)
- to + 10 (8)    7 (6)   N/A
  1. Note: + to - , change from positive to negative marker; - to +, change from negative to positive marker; ER, estrogen receptor; HER2, Human epidermal growth factor 2; HR, Hormone receptor; PR, progesterone receptor. *Data were available in a limited number of samples due to unknown information in the metastatic setting.
Back to article page